Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing

Pancreatic adenocarcinoma (PAC) is among the most lethal malignancies. While research has implicated multiple genes in disease pathogenesis, identification of therapeutic leads has been difficult and the majority of currently available therapies provide only marginal benefit. To address this issue,...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 7; no. 10; p. e43192
Main Authors Liang, Winnie S, Craig, David W, Carpten, John, Borad, Mitesh J, Demeure, Michael J, Weiss, Glen J, Izatt, Tyler, Sinari, Shripad, Christoforides, Alexis, Aldrich, Jessica, Kurdoglu, Ahmet, Barrett, Michael, Phillips, Lori, Benson, Hollie, Tembe, Waibhav, Braggio, Esteban, Kiefer, Jeffrey A, Legendre, Christophe, Posner, Richard, Hostetter, Galen H, Baker, Angela, Egan, Jan B, Han, Haiyong, Lake, Douglas, Stites, Edward C, Ramanathan, Ramesh K, Fonseca, Rafael, Stewart, A Keith, Von Hoff, Daniel
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 10.10.2012
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Pancreatic adenocarcinoma (PAC) is among the most lethal malignancies. While research has implicated multiple genes in disease pathogenesis, identification of therapeutic leads has been difficult and the majority of currently available therapies provide only marginal benefit. To address this issue, our goal was to genomically characterize individual PAC patients to understand the range of aberrations that are occurring in each tumor. Because our understanding of PAC tumorigenesis is limited, evaluation of separate cases may reveal aberrations, that are less common but may provide relevant information on the disease, or that may represent viable therapeutic targets for the patient. We used next generation sequencing to assess global somatic events across 3 PAC patients to characterize each patient and to identify potential targets. This study is the first to report whole genome sequencing (WGS) findings in paired tumor/normal samples collected from 3 separate PAC patients. We generated on average 132 billion mappable bases across all patients using WGS, and identified 142 somatic coding events including point mutations, insertion/deletions, and chromosomal copy number variants. We did not identify any significant somatic translocation events. We also performed RNA sequencing on 2 of these patients' tumors for which tumor RNA was available to evaluate expression changes that may be associated with somatic events, and generated over 100 million mapped reads for each patient. We further performed pathway analysis of all sequencing data to identify processes that may be the most heavily impacted from somatic and expression alterations. As expected, the KRAS signaling pathway was the most heavily impacted pathway (P<0.05), along with tumor-stroma interactions and tumor suppressive pathways. While sequencing of more patients is needed, the high resolution genomic and transcriptomic information we have acquired here provides valuable information on the molecular composition of PAC and helps to establish a foundation for improved therapeutic selection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Conceived and designed the experiments: WSL DWC JC MB MJB AKS DVH RKR RF GJW. Performed the experiments: WSL MB LP HB EB AB GHH JE. Analyzed the data: DWC TI SS AC JA AK WT CL. Contributed reagents/materials/analysis tools: RP HH DL ECS JK. Wrote the paper: WSL. Data interpretation: WSL MB JE MD GW DH JK.
Competing Interests: The authors have declared that no competing interests exist.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0043192